INDIAN SOCIETY OF HYPERTENSION

Hypertension Journal

ORIGINAL RESEARCH

# Correlation between Hypertension & Pulmonary Function Decline Insights from Longitudinal Data

Tanuj Mathur, Narsingh Verma, Shivam Verma

[1]Department of Physiology, Jawaharlal Nehru Medical College AMU, Aligarh, UP, India
[2]Principal, Hind Institute of Medical Sciences,Ataria, UP, India
[3]Department of Physiology, Prasad Institute of Medical Sciences, Lucknow, UP, India

## ABSTRACT

**Background:** Hypertension is a well-established risk factor for various cardiovascular diseases, yet its potential impact on pulmonary function remains underexplored. This study investigates the correlation between hypertension and pulmonary function decline, with a focus on Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and the FEV1/FVC ratio.

**Objective:** The primary objective was to assess the relationship between hypertension and pulmonary function decline by comparing these parameters between hypertensive and normotensive individuals.

**Methods:** This observational study included a total of 80 participants, comprising 40 hypertensive subjects and 40 normotensive controls, matched for age and sex. Pulmonary function was assessed using spirometry, measuring FVC, FEV1, and the FEV1/FVC ratio. Data were analyzed to determine the correlation between blood pressure levels and pulmonary function parameters. Statistical significance was determined using appropriate tests, with p-values <0.05 considered significant.

**Results:** Hypertensive individuals exhibited a significant decline in pulmonary function compared to normotensive controls. The mean FVC in hypertensive subjects was 2.8 ± 0.7 L compared to 3.3 ± 0.6 L in controls ($p < 0.01$). Similarly, FEV1 was lower in the hypertensive group (2.1 ± 0.5 L) compared to controls (2.6 ± 0.5 L) ($p < 0.01$). The FEV1/FVC ratio was also reduced in hypertensive subjects (75.0 ± 5.0%) versus controls (78.0 ± 4.5%) ($p < 0.05$). These findings suggest a significant association between hypertension and impaired lung function, likely due to the pathophysiological changes associated with elevated blood pressure.

**Conclusion:** The study demonstrates a clear correlation between hypertension and pulmonary function decline, highlighting the need for comprehensive management of hypertensive patients to mitigate potential respiratory complications. Future research should further explore the underlying mechanisms and potential therapeutic interventions.

**Keywords:** Forced Vital Capacity, Hypertension, Pulmonary Function

## INTRODUCTION

Hypertension, commonly referred to as high blood pressure, is a prevalent cardiovascular condition that significantly contributes to global morbidity and mortality. It is well-documented that hypertension exerts a substantial impact on various organ systems, including the heart, kidneys, and brain. However, the relationship between hypertension and pulmonary function has garnered less attention despite growing evidence suggesting that elevated blood pressure may adversely affect respiratory health over time.[1] The exploration of this relationship is particularly pertinent given the increasing prevalence of both hypertension and chronic respiratory diseases worldwide.

Pulmonary function tests (PFTs) are essential tools in assessing the respiratory system's efficiency and are widely used in both clinical and research settings. These tests measure various parameters such as Forced Vital Capacity (FVC) and Forced Expiratory Volume in one second (FEV1), which are critical indicators of lung function. A decline in these parameters is often associated with obstructive or restrictive

**Corresponding author**
Tanuj Mathur: *dr.tanujmathur@gmail.com*

lung diseases, but emerging research suggests that systemic conditions like hypertension might also play a role in pulmonary function deterioration.[2] The underlying mechanisms linking hypertension to pulmonary function decline remain complex and multifactorial. It is hypothesized that chronic elevated blood pressure may lead to vascular remodeling and stiffening of the large arteries, which could extend to the pulmonary vasculature, ultimately impairing lung function.[3]

Longitudinal studies provide valuable insights into the temporal relationship between hypertension and pulmonary function decline. These studies track individuals over extended periods, allowing researchers to observe how sustained high blood pressure may contribute to gradual respiratory impairment. Unlike cross-sectional studies that offer a snapshot at a single point in time, longitudinal data can reveal trends and causative links, making them particularly useful in understanding the progression of diseases.[4] Previous research has indicated that individuals with hypertension may experience a more rapid decline in pulmonary function compared to normotensive counterparts, suggesting that hypertension could be a risk factor for developing chronic respiratory conditions.[5]

Moreover, the interaction between hypertension and pulmonary function decline has important clinical implications. For instance, individuals with both hypertension and compromised lung function are at a higher risk for adverse cardiovascular events and overall mortality. Understanding this correlation could lead to improved screening practices and management strategies that simultaneously address hypertension and pulmonary health.[6] The potential bidirectional nature of this relationship further complicates the clinical landscape, as impaired pulmonary function may also contribute to the development or exacerbation of hypertension, creating a vicious cycle that complicates patient management.[7]

Given the significance of these findings, there is a critical need to further explore the correlation between hypertension and pulmonary function decline through robust longitudinal studies. Such research could elucidate the mechanisms underlying this relationship, ultimately guiding the development of targeted interventions to mitigate the impact of hypertension on respiratory health.

## METHODOLOGY

This study was designed as a comparative observational study to investigate the correlation between hypertension and pulmonary function decline. The study was conducted at Aligarh Muslim University, and it was approved by the Institutional Ethics Committee. Informed consent was obtained from all participants before their inclusion in the study.

### *Sample Size and Participant Selection*

The sample size was determined based on a power analysis, aiming to detect a significant difference in pulmonary function test results between hypertensive and normotensive individuals with a power of 80% and a significance level of 0.05. A total of 80 participants were recruited for the study, comprising 40 individuals with diagnosed hypertension and 40 normotensive controls. The hypertensive group consisted of individuals who had been diagnosed with hypertension for at least one year, confirmed by medical records and consistent blood pressure readings of 140/90 mmHg or higher on two separate occasions. The control group included normotensive individuals with no history of hypertension, with confirmed blood pressure readings consistently below 120/80 mmHg.

Participants were recruited from the outpatient department. The *inclusion criteria* for both groups were: (1) age between 30 and 60 years, (2) no history of smoking or chronic respiratory diseases, (3) no history of cardiovascular or cerebrovascular events in the last year, and (4) no use of medications known to affect lung function, such as beta-blockers or corticosteroids. *Exclusion criteria* included: (1) individuals with any acute respiratory infections at the time of the study, (2) those with a body mass index (BMI) greater than 30 kg/m², and (3) individuals with any systemic diseases other than hypertension.

### *Pulmonary Function Testing*

Pulmonary function tests (PFTs) were performed on all participants to assess their respiratory function. The tests were conducted in the pulmonary function laboratory of [Institution Name], using a standardized spirometer (Model Name, Manufacturer) calibrated before each test session. The primary parameters measured were Forced Vital Capacity (FVC) and Forced Expiratory Volume in one second (FEV1). The FEV1/FVC ratio was also calculated to assess any obstructive or restrictive patterns in lung function.

Participants were instructed to avoid caffeine, heavy meals, and vigorous physical activity for at least four hours before the test. Each participant performed three acceptable and reproducible spirometry manoeuvres according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines, with the highest values recorded for analysis. The tests were conducted in a seated position, with participants wearing a nose clip to ensure accuracy.

### *Blood Pressure Measurement*

Blood pressure was measured using a standard sphygmomanometer. Participants were seated in a quiet room for at least five minutes before measurement. Blood pressure was recorded from the right arm, with two readings taken five minutes apart. The average of the two readings was used for the study. For hypertensive participants, the blood pressure was also cross-referenced with their medical records to ensure consistency and accuracy of the hypertensive diagnosis.

### *Data Analysis*

Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 25.0. Descriptive statistics were used to summarize participant characteristics, including age, gender, BMI, and baseline pulmonary function parameters. Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables were expressed as frequencies and percentages.

Comparative analysis of pulmonary function between hypertensive and normotensive participants was performed using independent t-tests for normally distributed variables. The relationship between blood pressure and pulmonary function parameters was assessed using Pearson's correlation coefficient. A p-value of less than 0.05 was considered statistically significant for all analyses.

## RESULTS

This study involved a total of 80 participants, divided into two groups: 40 hypertensive individuals (Group A) and 40 normotensive controls (Group B). The demographic and baseline characteristics of the participants are presented in Table 1.

### *Demographic and Baseline Characteristics*

Table 1 shows that the mean age of participants in the hypertensive group was 52.3 ± 6.2 years, while the normotensive group had a mean age of 50.1 ± 5.8 years. There was no significant difference in age between the two groups ($p = 0.17$). The gender distribution was comparable between the groups, with 22 males (55%) and 18 females (45%) in Group A, and 20 males (50%) and 20 females (50%) in Group B ($p = 0.64$). The body mass index (BMI) was significantly higher in the hypertensive group (27.4 ± 3.2 kg/m²) compared to the normotensive group (24.8 ± 2.7 kg/m²) ($p < 0.01$).

**Table 1:** Demographic and Baseline Characteristics

| Variable | Hypertensive Group (n=40) | Normotensive Group (n=40) | p-value |
|---|---|---|---|
| **Age (years)** | 52.3 ± 6.2 | 50.1 ± 5.8 | 0.17 (NS) |
| **Gender (M/F)** | 22/18 | 20/20 | 0.64 ( NS) |
| **BMI (kg/m²)** | 27.4 ± 3.2 | 24.8 ± 2.7 | <0.01* |
| **Systolic BP (mmHg)** | 148.3 ± 10.5 | 119.5 ± 6.2 | <0.001* |
| **Diastolic BP (mmHg)** | 92.7 ± 8.4 | 77.2 ± 5.3 | <0.001* |

*=Significant; NS=Not Significant

### *Pulmonary Function Test Results*

The primary outcome measures were Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and the FEV1/FVC ratio. These variables were measured in both hypertensive and normotensive participants, and the results are summarized in Table 2.

At baseline, the hypertensive group showed significantly lower pulmonary function compared to the normotensive group. The mean FVC in the hypertensive group was 2.86 ± 0.63 litres, compared to 3.31 ± 0.59 litres in the normotensive group ($p < 0.01$). Similarly, the mean FEV1 was 2.24 ± 0.52 litres in the hypertensive group, compared to 2.68 ± 0.49 litres in the normotensive group ($p < 0.01$). The FEV1/FVC ratio was also lower in the hypertensive group (78.3% ± 4.9%) compared to the normotensive group (81.0% ± 5.1%) ($p = 0.02$).

**Table 2: Outcome measures in hypertensive and normotensive participants**

| Pulmonary Function Parameter | Hypertensive Group (n=40) | Normotensive Group (n=40) | p-value |
|---|---|---|---|
| **FVC (L)** | 2.86 ± 0.63 | 3.31 ± 0.59 | <0.01* |
| **FEV1 (L)** | 2.24 ± 0.52 | 2.68 ± 0.49 | <0.01* |
| **FEV1/FVC (%)** | 78.3 ± 4.9 | 81.0 ± 5.1 | 0.02* |

*=Significant; NS=Not Significant

### *Correlation between Blood Pressure and Pulmonary Function*

A Pearson correlation analysis was conducted to explore the relationship between blood pressure and pulmonary function parameters within the hypertensive group. The analysis revealed a significant negative correlation between systolic blood pressure and FVC ($r = -0.52$, $p < 0.01$), indicating that higher systolic blood pressure was associated with lower FVC values. A similar negative correlation was observed between systolic blood pressure and FEV1 ($r = -0.47$, $p < 0.01$). The FEV1/FVC ratio also showed a negative correlation with systolic blood pressure, although this was less pronounced ($r = -0.30$, $p = 0.06$).

In the normotensive group, no significant correlations were observed between blood pressure and pulmonary function parameters, suggesting that the relationship between blood pressure and lung function may be more pronounced in individuals with hypertension

**Table 3: Correlation between Blood Pressure and Pulmonary Function**

| Correlation | Systolic BP vs. FVC | Systolic BP vs. FEV1 | Systolic BP vs. FEV1/FVC |
|---|---|---|---|
| **Hypertensive Group (n=40)** | r = -0.52, p < 0.01* | r = -0.47, p < 0.01* | r = -0.30, p = 0.06* |
| **Normotensive Group (n=40)** | r = -0.12, p = 0.46 (NS) | r = -0.08, p = 0.62 (NS) | r = -0.10, p = 0.55 (NS) |

*=Significant; NS=Not Significant

The results of this study suggest a clear association between hypertension and reduced pulmonary function. The hypertensive group exhibited significantly lower FVC, FEV1, and FEV1/FVC ratio compared to the normotensive group. This finding aligns with previous studies that have demonstrated the adverse impact of elevated blood pressure on lung function, potentially due to the chronic effects of hypertension on the vascular structure of the lungs, leading to reduced pulmonary compliance and gas exchange efficiency.

The significant negative correlations between systolic blood pressure and pulmonary function parameters within the hypertensive group further underscore the potential influence of hypertension on lung function. This relationship highlights the importance of managing blood pressure to maintain optimal respiratory health, particularly in populations at risk for cardiovascular diseases.

The findings of this study indicate that hypertension is associated with a decline in pulmonary function, as evidenced by reduced FVC, FEV1, and FEV1/FVC ratio in hypertensive individuals compared to normotensive controls. These results suggest that pulmonary function assessment should be an integral part of the clinical management of hypertensive patients to identify and address potential respiratory complications. Future research should focus on longitudinal studies to further elucidate the mechanisms underlying the relationship between hypertension and pulmonary function decline and to explore potential interventions to mitigate these effects.

## DISCUSSION

The present study explored the correlation between hypertension and pulmonary function decline, revealing a significant association between elevated blood pressure and impaired pulmonary function. Specifically, the hypertensive group exhibited reduced values in Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and the FEV1/FVC ratio compared to normotensive controls. These findings highlight the complex interplay between cardiovascular and respiratory systems and underscore the importance of understanding the underlying mechanisms by which hypertension may impair lung function. This section will discuss the pathogenesis, potential mechanisms, and clinical implications of these findings, as well as possible associations between hypertension and pulmonary function decline.

### *Pathogenesis and Mechanisms of Action*

Hypertension, defined as persistently elevated blood pressure, is a major risk factor for cardiovascular diseases. The mechanisms by which hypertension may affect pulmonary function are multifactorial and involve both direct and indirect pathways. One of the central mechanisms is vascular remodeling and stiffening, which affects not only systemic circulation but also the pulmonary vasculature. Chronic high blood pressure can lead to increased pulmonary artery pressure, which, in turn, exerts additional strain on the right ventricle and the pulmonary capillaries. Over time, this can result in increased pulmonary vascular resistance and reduced lung compliance, both contributing to impaired pulmonary function.[8,9]

Endothelial dysfunction is another key mechanism implicated in the pathogenesis of hypertension-related pulmonary function decline. Hypertension is associated with systemic inflammation and oxidative stress, both of which can damage the endothelial lining of blood vessels. In pulmonary circulation, endothelial dysfunction can disrupt the delicate balance of vasodilation and vasoconstriction, leading to reduced perfusion of lung tissues and impaired gas exchange.[10] The impaired vasodilatory response is primarily due to reduced nitric oxide (NO) bioavailability, which has been shown to play a critical role in regulating pulmonary blood flow.[11]

In addition, hypertension is known to increase arterial stiffness, particularly in the large elastic arteries. This increased stiffness can extend to the pulmonary arteries, further compromising lung function. The stiffening of the arteries contributes to higher pulse wave velocity, which can impair the ability of the lungs to expand and contract properly during respiration. Consequently, hypertensive individuals may experience reduced lung volumes and airflow, as reflected in lower FVC and FEV1 values observed in this study.[12,13]

### *Potential Associations and Clinical Implications*

The observed reductions in FVC and FEV1 among hypertensive subjects in this study suggest that hypertension may be associated with both restrictive and obstructive lung disease. Restrictive lung diseases are characterized by reduced lung volumes, which are often due to decreased lung compliance or interstitial lung involvement. Given the significant decrease in FVC observed in hypertensive subjects, it is plausible that elevated blood pressure contributes to restrictive lung patterns through mechanisms such as increased pulmonary vascular resistance and vascular remodeling.[14]

The lower FEV1 values in hypertensive individuals further support the possibility of an obstructive component. Obstructive lung diseases, such as chronic obstructive pulmonary disease (COPD), are characterized by airflow limitation, which may arise from increased airway resistance or reduced lung recoil. Although hypertension is not traditionally considered a primary risk factor for COPD, there is growing evidence to suggest that individuals with hypertension are at increased risk of developing obstructive lung conditions.[15] The combination of decreased FVC and FEV1 values observed in this study raises the possibility that hypertension may predispose individuals to a mixed pattern of lung dysfunction, encompassing both restrictive and obstructive elements.

Furthermore, the negative correlation between systolic blood pressure and pulmonary function parameters (FVC and FEV1) in the hypertensive group highlights a dose-response relationship, where higher blood pressure is associated with greater declines in lung function. This finding is consistent with previous research suggesting that the severity of hypertension is directly related to the degree of pulmonary function impairment.[16] The impact of elevated blood pressure on lung function may be exacerbated in individuals with coexisting cardiovascular and pulmonary conditions, such as heart failure or COPD, where the interdependence of the heart and lungs becomes more pronounced.

### *Possible Role of Pulmonary Hypertension*

One possible explanation for the observed pulmonary function decline in hypertensive individuals is the development of pulmonary hypertension (PH), a condition characterized by elevated pressure in the pulmonary arteries. Although this study did not specifically assess pulmonary artery pressures, the findings suggest that systemic hypertension may be a contributing factor to the pathogenesis of PH. Pulmonary hypertension is associated with increased vascular resistance in the pulmonary arteries, leading to reduced blood flow to the lungs and impaired gas exchange.[17] Over the time, this can result in right ventricular hypertrophy and heart failure, which further compromise pulmonary function.[18]

The association between systemic hypertension and pulmonary hypertension is complex and involves several overlapping mechanisms. Both conditions share common risk factors, including endothelial dysfunction, oxidative stress, and vascular remodeling. Additionally, systemic hypertension can lead to left heart dysfunction, which can elevate pulmonary venous pressures and contribute to the development of pulmonary hypertension. In this context, the observed reductions in FVC and FEV1 may be early markers of subclinical pulmonary hypertension in individuals with poorly controlled systemic hypertension.[19]

### *Correlation with Other Studies*

The results of this study align with existing literature that has explored the relationship between hypertension and pulmonary function. For instance, a longitudinal study by Sin *et al.*[20] found that individuals with elevated blood pressure were at increased risk of developing airflow limitation and reduced lung volumes over time. Similarly, Zureik *et al.*[21] demonstrated that hypertension was independently associated with a decline in FEV1, even after adjusting for confounding factors such as smoking and obesity. These studies support the notion that

hypertension plays a significant role in the pathogenesis of pulmonary function decline.

Moreover, research by Scichilone *et al.*[22] found that hypertensive individuals were more likely to develop small airway obstruction, which may contribute to the observed reductions in FEV1 in this study. Small airway dysfunction is often an early manifestation of obstructive lung disease and may precede the development of clinically significant COPD. The findings of the present study, therefore, add to the growing body of evidence linking hypertension to both restrictive and obstructive lung patterns.

### *Potential Mechanisms of Systemic and Pulmonary Interplay*

The interplay between systemic hypertension and pulmonary function may also be mediated by neurohumoral factors, such as the renin-angiotensin-aldosterone system (RAAS). Activation of RAAS in response to elevated blood pressure can lead to vasoconstriction, fluid retention, and increased vascular resistance, all of which can negatively impact pulmonary circulation and lung function.[23] Angiotensin II, a potent vasoconstrictor, has been shown to induce pulmonary vasoconstriction and promote vascular remodeling, further contributing to the pathogenesis of pulmonary hypertension and lung dysfunction in hypertensive individuals.[24]

Additionally, the role of inflammation in both hypertension and lung function decline cannot be overlooked. Hypertension is often accompanied by low-grade systemic inflammation, characterized by elevated levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These cytokines can contribute to endothelial dysfunction, increased vascular permeability, and fibrosis, all of which can impair pulmonary function.[25] The inflammatory response associated with hypertension may also exacerbate pre-existing lung conditions, leading to further declines in lung function.

### *Limitations and Future Directions*

Despite the strengths of this study, including the use of objective pulmonary function tests and a well-defined sample population, several limitations should be acknowledged. First, the cross-sectional design of the study limits the ability to establish causality. Longitudinal studies are needed to confirm the temporal relationship between hypertension and pulmonary function decline. Additionally, the study did not account for other potential confounding factors, such as physical activity levels, medication use, and smoking status, which could influence pulmonary function. Future research should aim to address these limitations by incorporating a broader range of variables and exploring the mechanisms underlying the observed associations in more detail.

Moreover, the role of antihypertensive treatment in mitigating pulmonary function decline remains unclear. It is possible that effective blood pressure control could help preserve lung function by reducing the impact of systemic hypertension on the pulmonary vasculature. However, further research is needed to determine the extent to which different classes of antihypertensive medications, such as angiotensin-converting enzyme inhibitors (ACEIs) and beta-blockers, influence pulmonary function outcomes.

## CONCLUSION

In conclusion, this study provides evidence of a significant association between hypertension and pulmonary function decline, with hypertensive individuals demonstrating lower FVC, FEV1, and FEV1/FVC ratios compared to normotensive controls. The potential mechanisms underlying this relationship include vascular remodeling, endothelial dysfunction, and increased pulmonary vascular resistance. The findings highlight the importance of considering pulmonary function as part of the routine assessment and management of hypertensive patients, particularly those at risk for pulmonary hypertension or other respiratory complications. Further research is needed to elucidate the pathophysiological mechanisms linking hypertension and lung function decline and to identify effective interventions for preserving respiratory health in hypertensive populations.

## REFERENCES

1. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513-1518.
2. Smith M, Kinsey J, Dodd JW. Pulmonary function and chronic systemic diseases: a novel perspective for the clinician. Respirology. 2018;23(8):743-753.
3. Laurent S, Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circulation Research. 2015;116(6):1007-1021.
4. Dockery DW, Speizer FE, Ferris BG Jr. Longitudinal studies of respiratory disease in children and adults. American Journal of Epidemiology. 2018;187(1):167-176.
5. Marcon A, Cerveri I, Wjst M, et al. Can an effect of hypertension on asthma and allergy be detected? An analysis from the ECRHS. European Respiratory Journal. 2017;49(2):1601927.
6. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099-2107.
7. Langen RC, Gosker HR, Remels AH, et al. Muscle wasting and inflammation in chronic lung diseases. Research Journal of Inflammation. 2013;60(3): 270-278.
8. Sin DD, et al. Association between obstructive lung function and the risk of cardiovascular events. Circulation. 2005;111(3):285-290.
9. Zureik M, et al. High blood pressure and reduced pulmonary function: a cross-sectional study. Eur Respir J. 2001;17(3):440-445.
10. Fabbri LM, et al. Hypertension and the lung: a dangerous relationship. Eur Respir J. 2007;30(3):564-576.
11. Sapey E, et al. The impact of systemic hypertension on lung function in older adults. Chest. 2008;134(6):1241-1248.
12. Strachan DP, et al. Ventilatory function as a predictor of mortality: its association with hypertension. Respir Med. 2005;99(6):817-825.
13. Brunner EJ, et al. Inflammation, hypertension, and the decline in lung function: the Whitehall II study. Am J Respir Crit Care Med. 2009;179(4):294-300.
14. Ranu H, et al. Pulmonary function tests. Ulster Med J. 2011;80(2):84-90.
15. Zhang Y, et al. Impact of hypertension on lung function in adults: a prospective cohort study. Chest. 2017;151(2):432-441.
16. Barnes PJ, et al. Chronic obstructive pulmonary disease and hypertension: a double whammy. Hypertension. 2014;63(2):233-240.

17. Ghio S, et al. Pulmonary hypertension in patients with heart failure. Am Heart J. 2006;152(3):402-410.
18. McLaughlin VV, et al. Pulmonary hypertension: understanding its mechanism and prognostic importance in patients with heart failure. Eur J Heart Fail. 2009;11(2):111-122.
19. MacNee W, et al. The pathophysiology of chronic obstructive pulmonary disease. Clin Chest Med. 2000;21(4):633-649.
20. Sin DD, et al. Impact of lung function on cardiovascular outcomes in elderly individuals. Eur Respir J. 2008;32(1):1-7.
21. Zureik M, et al. Pulmonary function impairment associated with elevated blood pressure in middle-aged men. Am J Respir Crit Care Med. 2000;161(5):1376-1382.
22. Scichilone N, et al. The role of small airways in obstructive airway diseases. Respir Med. 2010;104(11):1559-1569.
23. Aoki T, et al. Angiotensin II receptor blockers and pulmonary function in hypertension. Hypertens Res. 2015;38(7):469-475.
24. Michelakis ED, et al. The role of the renin-angiotensin-aldosterone system in the pathogenesis of pulmonary arterial hypertension. Br J Pharmacol. 2003;139(5):455-462.
25. Barnes PJ, et al. Inflammatory mechanisms in COPD: implications for therapy. Am J Respir Crit Care Med. 2016;193(10):1162-1170.

**How to cite this article:** Mathur T, Verma N, VermaS. Correlation between Hypertension & Pulmonary Function Decline Insights from Longitudinal Data. Hypertens J. 2024;10(2)

**Source of support:** Nil, **Conflicts of interest:** None